Opinion|Videos|July 22, 2024
The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
- How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
- What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
- How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
5